Corporate governance

In order to secure strong and sustainable corporate governance, it is important that Oncoinvent (the “Company") ensures good and healthy business practices, reliable financial reporting and an environment of compliance with legislation and regulations.

The Company has governance documents setting out principles for how business should be conducted. References to certain more specific policies are included in this corporate governance policy where relevant. The Company’s governance regime is approved by the board of directors in the Company. Where such documents have been approved before the merger between BerGenBio and Oncoinvent completed 29 October 2025 and the change of name from BerGenBio ASA to Oncoinvent ASA, the documents may include the name BerGenBio.

The Company is incorporated and registered in Norway and is subject to Norwegian law. The Company’s shares are listed on Oslo Stock Exchange (Oslo Børs). As an issuer of shares, the Company must comply with rules applicable for companies with shares listed on Oslo Stock Exchange and rules applicable for public limited companies in general.

The Company endorses the Norwegian Code of Practice for Corporate Governance (Nw.: Norsk anbefaling for eierstyring og selskapsledelse), issued by the Norwegian Corporate Governance Board.

The annual Corporate Governance report is included in the Governance section of the Annual report available here.

Nomination Committee

The Nomination Committee of Oncoinvent ASA consists of two members, elected pursuant to section 9 of its articles of association. The majority of the members of the Nomination Committee shall be independent of the Company’s board of directors and the management. Members are elected for two years at a time.

The Company’s general meeting elects the members of the Nomination Committee and determines their remuneration.

The Nomination Committee shall recommend:

• candidates for the election of members and chairman to the Board of Directors; and
• remuneration of the Board of Directors.

The Nomination Committee consists of Lars Lund Roland (Chair) and Leiv Askvig and can be reached atoncoinvent@oncoinvent.com.

Remuneration Committee

The remuneration committee is a sub-committee of Oncoinvent ASA’s board of directors and its objective is to act as a preparatory and advisory body in relation to the Company’s remuneration of executive management. The purpose of the Remuneration Committee is to ensure thorough and independent preparation of matters relating to compensation to the executive personnel. The majority of the committee members should be independent of the Company’s operations.

In particular, the Remuneration Committee shall:

• review the remuneration and benefits strategy for the members of the executive management of Oncoinvent;
• review the performance of the executive management versus the adopted objectives and recruitment policies, career planning, and management development plans; and
• prepare matters relating to other material employment issues in respect of the executive management.

The remuneration committee consists of:
Gillies O'Bryan-Tear (Chair) and Kari Grønås.

Remuneration policy approved by AGM 24 May 2024

The Company will on an annual basis and as part of the Annual Report publish a Remuneration Report pursuant to section 6-16a of the Norwegian Public Limited Companies Act. The report is available in the Governance section of the annual report available on the Company’s website in the Investor/Financial report section here.

Audit Committee

The audit committee is a sub-committee of Oncoinvent ASA’s board of directors and its objective is to act as a preparatory body in connection with the Board of Directors’ supervisory roles with respect to financial reporting and the effectiveness of the Company’s internal control system, and other tasks assigned to the audit committee in accordance with the provisions set forth in these instructions.

The Audit Committee supports the Board of Directors in the administration and exercise of its responsibility for supervision in accordance with applicable provisions of the Norwegian Public Limited Companies Act and Norwegian securities legislation, as well as applicable listing standards of Oslo Stock Exchange.

The audit committee consists of:
Hilde Steineger (Chair), Olav Hellebø and Orlando Oliveira.